“Novo Nordisk launched the pill version of its popular GLP-1 weight loss drug Wegovy in the US on Monday, marking a new era in obesity treatment.

The debut of the medication, the first of its kind, is set to accelerate a price war, given that it is priced significantly lower than the jab-based versions. The Danish pharmaceutical giant, which also makes Ozempic, had a rough 2025 as it lost ground to American rival Eli Lilly, but it is banking on the weight loss pill to regain its advantage.”

From Semafor.